When Surgery Alone Isn’t Enough for a Dog’s Eye Tumor
Finding out your dog has an eye tumor is frightening. Surgery is often the first step — but sometimes the tumor can’t be fully removed, and removing the entire eye feels like too drastic a step. A recently published case report in Veterinary Ophthalmology describes one possible way forward: using chemotherapy eye drops after incomplete surgery to manage a type of eye tumor called a conjunctival melanoma in a single dog.
Conjunctival melanoma is a tumor that grows on the conjunctiva — the thin, moist tissue that lines the inside of the eyelids and covers part of the eyeball. It’s not common, but when it appears, deciding on the best treatment can be difficult, especially if the tumor can’t be completely cut out.
Why Incomplete Tumor Removal Creates a Hard Decision
In an ideal situation, a surgeon removes a tumor with clean margins — meaning no cancer cells are left at the edges. But that isn’t always possible, especially with tumors near delicate eye structures. When some tumor remains after surgery, veterinarians face a difficult choice: perform more aggressive surgery (which might mean removing the entire eye), or try another approach.
The case described in this report involved a 15-year-old spayed female Shih Tzu with a conjunctival mass in the right eye. The tumor was an amelanotic melanoma — a type that lacks the dark pigment (color) normally associated with melanoma, making it harder to spot and define at the edges. Ophthalmic and physical examinations, along with computed tomography (CT), confirmed that the tumor was confined to the conjunctiva with no systemic metastases, although the mass had spread throughout the bulbar conjunctiva and the third eyelid.
After the owners declined exenteration — surgical removal of the eye and the contents of the eye socket — the veterinary team performed a debulking surgery. Histopathology and immunohistochemistry confirmed malignant amelanotic melanoma with incomplete surgical margins.
About This Case: One Dog, One Treatment Approach
This is a case report — meaning it describes the experience of a single dog, not a large study with many patients. A case report is the first step in documenting a treatment approach that hasn’t been widely described before. It’s an important form of medical documentation, but it cannot prove that a treatment works or is safe across many patients.
In this case, the veterinary team applied topical mitomycin C to the dog’s eye after the initial surgery and after the conjunctiva had healed. Mitomycin C is a chemotherapy drug — a medication that targets and kills rapidly dividing cells like cancer cells. When used topically (applied directly to the surface of the eye as drops or a solution), it works locally without exposing the whole body to chemotherapy.
The goal was to manage any remaining tumor cells at the surgical site while preserving the eye itself.
The protocol used by this veterinary team in this one case was 0.04% mitomycin C ophthalmic solution four times daily for one month. That is a report of what was done for this patient, not a home treatment plan or a protocol owners should try to replicate.
What the Case Report Found
The report describes topical mitomycin C as a potential eye-sparing or globe-preserving option — a way to address leftover tumor cells without the need for more invasive surgery or eye removal. During the 14-month postoperative follow-up period, physical and ophthalmic examinations found no clinical evidence of local tumor recurrence.
The report also documents side effects in this dog. During topical mitomycin C therapy, the dog developed superficial corneal epithelial defects (small surface injuries on the clear front of the eye) and conjunctival hyperemia (redness from increased blood flow in the conjunctiva). These resolved after the medication was discontinued. During long-term follow-up, reduced tear production was also noted and was managed with topical cyclosporine.
However, the authors are careful about what this single case can and cannot tell us:
- The approach may offer an alternative when more radical surgery is declined
- It does not establish how effective this treatment is compared to other options
In plain terms: one dog received this treatment, and the report documents that experience, including 14 months without clinical evidence of local recurrence and documented eye-surface and tear-production side effects. We do not have data on how often this approach succeeds or whether it would work in other dogs with similar tumors.
A Possible Option Worth Asking Your Vet About
If your dog is ever diagnosed with an eye tumor that can’t be fully removed, this case report adds to the small body of knowledge about alternatives to eye removal. Topical chemotherapy drops are not a new concept in human eye cancer care, and this report suggests veterinary teams may consider them in dogs as well.
That said, this is still early, limited evidence — one documented case. If your dog is in this situation, the right conversation is with a veterinary ophthalmologist (an eye specialist for animals) and ideally a veterinary oncologist (a cancer specialist). They can review what’s known, weigh the options, and help you understand what might be appropriate for your individual dog.
Signs That Warrant a Prompt Vet Visit
Eye problems in dogs can progress quickly. Contact your veterinarian promptly if you notice:
- A new lump or growth near your dog’s eye or eyelid
- Redness, swelling, or discharge that does not clear up within a day or two
- Your dog squinting, pawing at the eye, or keeping it partially closed
- A change in the appearance of the eye surface or surrounding tissue
Catching eye tumors early — before they grow and spread — gives veterinarians more options and generally leads to better outcomes.
Limitations of This Case Report
A single case report is the lowest level of clinical evidence. It documents one patient’s experience, which can suggest possibilities but cannot confirm that a treatment is safe or effective for other patients. The authors acknowledge that this approach does not establish comparative efficacy — meaning we don’t know how topical mitomycin C performs compared to other treatments, or whether it would provide lasting tumor control in other dogs.
Side effects were documented in this one dog, but a single case cannot show how frequently those effects occur or how serious they might be across dogs treated this way. Much larger studies — with multiple dogs and longer follow-up — would be needed before this approach could be recommended broadly.
The Bottom Line
A published case report describes topical mitomycin C eye drops used in a single dog after incomplete surgical removal of a conjunctival melanoma, suggesting this may be an eye-sparing approach when more radical surgery is not pursued. In this dog, the veterinary team reported no clinical evidence of local tumor recurrence during 14 months of postoperative follow-up, along with documented side effects that resolved or were managed. The evidence comes from one case only and does not establish efficacy, safety, or long-term outcomes for other dogs.
If your dog develops an eye tumor, the most important step is prompt veterinary evaluation. Ask for a referral to a veterinary ophthalmologist or oncologist when a more complex eye condition is suspected — they will have the most current knowledge of available options and can help you weigh what’s right for your pet.
This article summarizes peer-reviewed research for educational purposes. Always consult with your veterinarian for personalized advice about your pet’s health and behavior.
